TY - JOUR T1 - Machine learning for ovarian cancer: lasso regression-based predictive model of early mortality in patients with stage I and stage II ovarian cancer JF - medRxiv DO - 10.1101/2020.05.01.20088294 SP - 2020.05.01.20088294 AU - Robert Chen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20088294.abstract N2 - While machine learning has shown promise in prediction of mortality in situations such as intensive care units, there is limited evidence of its application towards ovarian cancer.In this study, we extracted clinical covariates from a cohort of 273 patients with stage I and II ovarian cancer, and trained a machine learning algorithm, L2-regularized logistic regression, on the set of patients in prediction problem for mortality less than 20 months, representing the 25th percentile of overall survival.Our model achieves an AUC of 0.621, accuracy 0.761, sensitivity 0.130, positive predictive value 0.659, and F1 score 0.216. This study serves as a proof of concept for a predictive model customized towards mortality prediction for malignant neoplasm of the left testis, and can be adapted and generalized to related tumors such as spermatic cord and scrotal tumor types.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/A.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublic data were used. https://seer.cancer.gov/ ER -